Anticipating the need for new molecules and novel therapy areas, Neopharma Japan was established in October 2016, as a subsidiary of Neopharma to enable development, manufacturing and marketing of 5 – ALA based products.

Neopharma Japan’s facilities include a manufacturing facility, NeoALA Japan, in Fukuroi. Acquired from CosmoALA Japan, in 2016, NeoALA Japan focuses on R&D and manufacturing of 5 – ALA based products.

Click here to know more about Neopharma Japan

Neopharma through its Japanese subsidiary neoALA Co. Ltd. Japan acquired the Japanese injectable business and related assets belonging to Kyowa (Kyowa Pharmaceutical Industry Co. Ltd.), subsidiary of Lupin Limited. The plant and associated facilities are based out of Atsugi, Japan and would be engaged in the manufacturing and commercialization of injectable products in the critical care segment.

Established in 2008, Neobiocon FZ is a 50 - 50 joint venture between Neopharma and Biocon to manufacture and market biopharmaceuticals and in – license products.

In 2012, as a part of its portfolio expansion, Neopharma entered into a manufacturing and marketing joint venture with Hetero Drugs.